SCHEMBL15670229

SCHEMBL15670229

N[C@H](c1ccccc1O)[C@H](N)c1ccccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.56
GABRB2 P47870 1/20 0.56
TSHR P16473 3/20 0.50
ALDH1A1 P00352 4/20 0.47
ALOX15 P16050 3/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
POLB P06746 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
EGFR P00533 2/20 0.47
CA2 P00918 2/20 0.47
LMNA P02545 2/20 0.47
FYN P06241 2/20 0.47
MMP9 P14780 2/20 0.47
RECQL P46063 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
NPC1 O15118 1/20 0.47
CA12 O43570 1/20 0.47
GMNN O75496 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25415814 1.00 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL4681487 1.00 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL3833921 1.00 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL30369671 1.00 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL29424779 1.00 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL18650079 0.83 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL3949185 0.83 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL29395043 0.83 GABRA1 (0.56) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL640127 0.81 GABRA1 (0.54) GABRA1GABRB2TSHRALDH1A1ALOX15
SCHEMBL5597399 0.80 GABRA1 (0.43) GABRA1GABRB2TSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US disclosed
WO-2023099623-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-06-08 WO disclosed
WO-2023099623-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-06-08 WO disclosed
US-10392353-B2 Processes for making substituted quinazoline compounds using hydrogen bonding catalysts MERCK SHARP & DOHME CORP. (US) 2019-08-27 US disclosed
US-10392353-B2 Processes for making substituted quinazoline compounds using hydrogen bonding catalysts MERCK SHARP & DOHME CORP. (US) 2019-08-27 US disclosed
US-20180346429-A1 NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS MERCK SHARP & DOHME CORP. (US) 2018-12-06 US disclosed
US-20180093992-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME LLC 2018-04-05 US disclosed
US-20180093992-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME LLC 2018-04-05 US disclosed
US-9862725-B2 Process for preparing chiral dipeptidyl peptidase-IV inhibitors MERCK SHARP & DOHME CORP. (US) 2018-01-09 US disclosed
US-9701684-B2 Chiral fluorinating reagents OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2017-07-11 US disclosed
US-20170158701-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME LLC 2017-06-08 US disclosed
US-20170158701-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME LLC 2017-06-08 US disclosed
WO-2017091453-A1 NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS MERCK SHARP & DOHME CORP. (US) 2017-06-01 WO disclosed
WO-2016014324-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-01-28 WO disclosed
US-20150284401-A1 CHIRAL FLUORINATING REAGENTS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2015-10-08 US disclosed
EP-2914582-A2 CHIRAL FLUORINATING REAGENTS Isis Innovation Limited (GB) 2015-09-09 EP disclosed
WO-2014068341-A2 CHIRAL FLUORINATING REAGENTS ISIS INNOVATION LIMITED (GB) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284401-A1 CHIRAL FLUORINATING REAGENTS TIAM1, AFF2, AFF1 GABRA1 1083/4885GABRB2 1412/4885TSHR 1267/4885
US-20180093992-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, PEPD, DPP9 GABRA1 3000/4885GABRB2 2341/4885TSHR 2099/4885
US-20170158701-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, PEPD, DPP9 GABRA1 3026/4885GABRB2 2372/4885TSHR 2106/4885
US-10392353-B2 Processes for making substituted quinazoline compounds using hydrogen bonding catalysts NQO1, NDUFS7, NDUFS2 GABRA1 3388/4885GABRB2 3247/4885TSHR 4787/4885
US-20180346429-A1 NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS NQO1, NDUFS3, SDHA GABRA1 3789/4885GABRB2 3532/4885TSHR 4833/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 GABRA1 2143/4885GABRB2 2414/4885TSHR 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.